合景悠活(03913.HK)向16名參與者授出合共144.4萬股獎勵股份
格隆匯7月23日丨合景悠活(03913.HK)發佈公吿,董事會已採納合資格參與者將有權參與的股份獎勵計劃。根據計劃規則,獨立受託人將購入股份,並以信託方式代入選參與者持有,直至股份根據計劃規則歸屬為止。已歸屬股份將無償轉讓予入選參與者。於計劃年期內根據計劃將予授出的股份數目以公司於採納日期已發行股份總數的5%為限。
董事會已進一步決議批准向16名入選參與者(包括5名關連承授人及11名普通僱員)授出合共144.4萬股獎勵股份。有關獎勵股份將透過於聯交所購買現有股份的方式授出。獎勵股份相當於公司於本公吿日期的已發行股本的約0.0716%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.